Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol RIN1 contributors: mct/npt/pgu - updated : 23-05-2016
HGNC name Ras and Rab interactor 1
HGNC id 18749
Location 11q13.2      Physical location : 66.099.541 - 66.104.000
Synonym name
  • RAS inhibitor protein 1
  • Ras inhibitor JC99
  • Ras interaction/interference protein 1
  • DNA
    TYPE functioning gene
    STRUCTURE 5.07 kb     10 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    MAPPING cloned Y linked   status confirmed
    Map cen - VEGFB - D11S750 - RIN1 - SLC29A2 - D11S913 - FRA11A - CCND1 - FGF4 - FGF3 - CTTN - NUMA1 - UVRAG - LRRC32 - FRA11F - qter
    Physical map
    P5326 11q13.1 hypothetical protein p5326 DRAP1 11q13.3 DR1-associated protein 1 (negative cofactor 2 alpha) FLJ32880 11q13.1 hypothetical protein FLJ32880 SART1 11q12-q13 squamous cell carcinoma antigen recognised by T cells MGC11102 11q13.1 hypothetical protein MGC11102 BANF1 11q13.1 barrier to autointegration factor 1 CST6 11q13.2 cystatin E/M CATSPER1 11q12.1 cation channel, sperm associated 1 GAL3ST2 11q13 cation channel, sperm associated 1 SF3B2 11cen-q23 splicing factor 3b, subunit 2, 145kDa PACS1 11q13.1 phosphofurin acidic cluster sorting protein 1 KLC2 11q13.1 phosphofurin acidic cluster sorting protein 1 RAB1B 11q12 RAB1B, member RAS oncogene family MGC50896 11q13.1 hypothetical protein MGC50896 YIF1 11q13 Yip1 interacting factor homolog (S. cerevisiae) MGC33486 11q13.1 hypothetical protein MGC33486 LOC387783 11 LOC387783 CD164L1 11q13 CD164 sialomucin-like 1 RIN1 11q13.2 Ras and Rab interactor 1 BRMS1 14q13.1 breast cancer metastasis-suppressor 1 B3GNT6 11q13.1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 SLC29A2 11q13 solute carrier family 29 (nucleoside transporters), member 2 LOC387784 11 LOC387784 NXF 11q13 HLH-PAS transcription factor NXF MRPL11 11q13.3 mitochondrial ribosomal protein L11 MGC35521 11q13.1 pellino 3 alpha DPP3 11q12-q13.1 dipeptidylpeptidase 3 BBS1 11q13 Bardet-Biedl syndrome 1 LOC254359 11q13.1 hypothetical protein LOC254359 ACTN3 11q13 actinin, alpha 3 CTSF 11q13.1-q13.3 cathepsin F FLJ10786 11q13.1 hypothetical protein FLJ10786 CCS 11q13 copper chaperone for superoxide dismutase
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    10 - 2698 - 783 - 2009 19806790
    - - 612 - - expressed primarily in the cytoplasm and no expression in the cell membrane, in gastric and colon cancer cell lines 2009 19806790
  • contain a tyrosine phosphorylation site on the 5prime side and Ras and 14-3-3 binding domains on the 3prime side, indicating that it is a product with a different splicing pattern
  • had a structure conserving the Ras and 14-3-3 binding domains, but lacking two tyrosine phosphorylation sites
    Type widely
       expressed in (based on citations)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Endocrinepancreas   highly
    Nervousbrain   highly
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    cell lineage
    cell lines
    at STAGE
    physiological period pregnancy
    Text placenta
  • one SH2 domain
  • a 3prime domain that binds to H-Ras protein
  • a RIN homology domain
  • a C-terminal Vps9 domain
  • multidomain Rab5 exchange factors family
  • RIN (Ras interaction/interference) family
  • CATEGORY regulatory , signaling
    SUBCELLULAR LOCALIZATION     plasma membrane
    basic FUNCTION
  • functioning as an effector or regulator of RAS
  • regulates endocytosis of the EPHA4 receptor in mature excitatory neurons (Deininger 2008)
  • play an important role in the endocytosis of the epidermal growth factor receptor (EGFR)
  • regulates EGFR degradation in cooperation with STAM, defining a novel role for Rin1 in regulating endosomal trafficking
  • serves as an important signal transduction system for evaluating the malignancy of colorectal cancer
  • RAS effector regulating epithelial cell properties
  • acting as a negative regulator of tumor cell invasive growth and that this requires the ABL kinase-signaling function of RIN1, suggesting a mechanism through which RIN1 silencing may contribute to breast cancer progression
  • selective association of RAB5A and RIN1 contributes to the dominance of RAB5A in EGFR trafficking, whereas RAB5B, RAB5C may have major functions unrelated to the EGFR degradation pathway
  • RAS effector protein involved in the regulation of epithelial cell processes such as cell migration and endocytosis
  • growth factor-directed cell migration, a physiological process that involves receptor endocytosis and actin remodeling, also requires the ability of RIN1 to coordinate RAB5 GTPase and ABL tyrosine kinase pathways
  • is a host cell regulator that performs counterbalancing functions during early and late stages of L. monocytogenes infection
  • novel PRKD1 signaling pathway through RIN1 and Abl kinases that is involved in the regulation of actin remodeling and cell migration
  • a component
    small molecule
  • 14.3.3 proteins and proteins containing SH3 domain
  • interacts with signal-transducing adaptor molecule 2 (STAM2), a protein that associates with hepatocyte growth factor-regulated substrate and plays a key role in the endosomal sorting machinery
  • RIN1, RIN2, RIN3 serve as guanine nucleotide exchange factors for RAB5A
  • RIN1 directly activates ABL tyrosine kinases, which regulate actin remodeling, a function not previously connected to endocytosis
  • EGFR activation also promotes RIN1 interaction with BIN1, a membrane bending protein
  • MFN2 and RIN1 are new SMAD2 binding partners required for mitochondrial fusion
  • cell & other
    Other specific Ser291/292 phosphorylation of RIN1 favoured binding to activated RAS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --low  
    often reduced in human breast tumor cells compared with morphologically normal breast glandular cells
    tumoral     --other  
    aberrant accumulation associates with poor prognosis in melanoma
    Variant & Polymorphism
    Candidate gene
    Therapy target
    RIN1 targeting could be efficacious for imatinib-resistant disease and might complement ABL kinase inhibitors in first-line therapy in leukemia